<DOC>
	<DOCNO>NCT02256501</DOCNO>
	<brief_summary>According high morbidity mortality idiopathic Dilated CardioMyopathy ( IDCM ) pediatric , new modality treatment emerge . There case report administration stem cell therapy . The investigator design first randomize clinical trial setting . The investigator enroll 32 pediatric IDCM patient two group ( 16 pt . group include cell therapy control ) . The investigator assess safety efficacy intracoronary transplantation autologous bone marrow derive mononuclear cell patient compare control group .</brief_summary>
	<brief_title>Intracoronary Transplantation Bone Marrow Derived Mononuclear Cells Pediatric Cardiomyopathy</brief_title>
	<detailed_description>Dilated cardiomyopathy common form cardiomyopathy rare life-threatening disorder child . The primary cause nearly 37 % child DCM unknown diagnosis . Despite develop medical surgical treatment past several decade , standard treatment ( include Digitalis , diuretic , inhibitor ACE , beta blocker , antiplatelet drug treatment Antiarrhythmic ) , may stabilize condition , restore heart function previous condition . Therapy remain complex expensive . For child heart transplantation option mortality continue high , also . Stem cell cell-based therapy offer innovative approach reverse cardiac structure function towards normal , possibly reduce need aggressive therapy cardiac transplantation . According inclusion exclusion criterion trial , 32 patient leave ventricular ejection fraction le 45 % resistance standard medical therapy randomly allocate 2 group include BM-derived mononuclear ( n=16 ) control ( n=16 ) . Only MNC group undergo bone marrow aspiration intracoronary injection . The investigator follow patient 2 week , 1 , 2 , 4 6 month transplantation cell therapy group registration placebo physical examination , laboratory test image echocardiography , CXR CMR .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>1 . Age 116 year ( ) 2 . LVEF &lt; 45 % ( echocardiography ) 3 . Duration diagnosis 3 month 4 . Resistance Standard therapy 2 month 5 . Informed consent 1 . Congenital Heart Disease 2 . Active infection less one month 3 . Dysrhythmia 4 . Cardiogenic shock 5 . Renal failure 6 . Immune Deficiency ( Documentation ) 7 . Terminal illness malignancy ( Documentation ) 8 . TORCH ( Documentation ) 9 . Metabolic disorder ( Documentation ) 10 . Neuromuscular disorder ( Documentation ) 11 . Autoimmune disease ( Documentation ) 12 . Developmental delay 13 . Cytotoxic drug 14 . Previous bone marrow transplant 15 . Contraindications CMR metallic implant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Dilated cardiomyopathy pediatric heart failure cell therapy</keyword>
</DOC>